Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc

Bullboard Posts

Comment by DatAssBanditon Jun 12, 2018 1:19pm

96 Views

Post# 28160537

RE:RE:RE:ANONYMOUS ON THE BID

Gussto wrote:

Level ll Quote

Bid Ask

Price Total Size # of Orders Price Total Size # of Orders

$0.17 216000 14 $0.175 77000 5

$0.165 367500 12 $0.18 335500 8

$0.16 327000 14 $0.185 187000 17

$0.155 91500 6 $0.19 287500 18

$0.15 52000 9 $0.195 216500 5

$0.145 225000 7 $0.20 330500 11

$0.14 186500 7 $0.205 32500 2

$0.135 98000 5 $0.21 12000 2

$0.13 181000 12 $0.215 5500 1

$0.125 115000 7 $0.22 24500 4